JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

The combination of serum lncRNA PTTG3P and mRNA PTTG1 serves as a diagnostic and prognostic marker for hepatocellular carcinoma

  • 0Department of Laboratory Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120, P.R. China.
Molecular Medicine Reports +

|

December 5, 2024

|

December 5, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Serum long noncoding RNA (lncRNA) PTTG3P and mRNA PTTG1 show promise as biomarkers for hepatocellular carcinoma (HCC). A combination including PTTG3P, PTTG1, and alpha-fetoprotein (AFP) offers a highly sensitive and specific noninvasive diagnostic tool for HCC.

Area Of Science

  • Biochemistry
  • Molecular Biology
  • Oncology

Background

  • Hepatocellular carcinoma (HCC) poses a significant global health challenge.
  • Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development.
  • PTTG3P, a lncRNA, and PTTG1, its target mRNA, are implicated in HCC pathogenesis.

Purpose Of The Study

  • To evaluate the diagnostic accuracy of serum PTTG3P and PTTG1 for hepatocellular carcinoma (HCC).
  • To assess the combined diagnostic efficacy of PTTG3P, PTTG1, and other established biomarkers for HCC.
  • To explore the potential of these molecules as noninvasive biomarkers for HCC diagnosis and prognosis.

Main Methods

  • Quantification of serum PTTG3P and PTTG1 expression using reverse transcription-quantitative PCR in 373 participants (HCC, chronic hepatitis B, liver cirrhosis, healthy controls).
  • Analysis of the association between serum PTTG3P and clinical characteristics.
  • Receiver operating characteristic (ROC) curve and area under the curve (AUC) analyses to determine diagnostic performance.

Main Results

  • Serum PTTG3P and PTTG1 levels were significantly elevated in HCC and chronic hepatitis B patients compared to healthy controls.
  • Postoperative levels of PTTG3P and PTTG1 decreased significantly in HCC patients.
  • A combination of PTTG3P, PTTG1, AFP, ALT, AST, GGT, and ALP achieved an AUC of 0.959, with 90.4% sensitivity and 98.0% specificity for HCC diagnosis.

Conclusions

  • Serum PTTG3P and PTTG1 are potential diagnostic biomarkers for hepatocellular carcinoma (HCC).
  • The combination of PTTG3P, PTTG1, and AFP demonstrates high sensitivity and specificity for noninvasive HCC diagnosis.
  • This multi-biomarker panel offers a promising approach for early and accurate detection of HCC.

Keywords: